Kane Biotech Inc.
KNBIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | – | – | – | – |
| - Cash | $359 | $749 | $1,105 | $1,153 |
| + Debt | $1,713 | $2,175 | $2,579 | $2,203 |
| Enterprise Value | – | – | – | – |
| Revenue | $2,081 | $149 | $2,668 | $1,608 |
| % Growth | 1,296.8% | -94.4% | 66% | – |
| Gross Profit | $872 | $109 | $1,413 | $568 |
| % Margin | 41.9% | 73.5% | 53% | 35.4% |
| EBITDA | -$3,707 | -$3,234 | -$2,947 | -$4,246 |
| % Margin | -178.2% | -2,171% | -110.5% | -264.1% |
| Net Income | $6,098 | -$5,034 | -$3,890 | -$4,605 |
| % Margin | 293% | -3,379% | -145.8% | -286.4% |
| EPS Diluted | -0.024 | -0.036 | -0.033 | -0.041 |
| % Growth | 34.3% | -7.8% | 18.6% | – |
| Operating Cash Flow | – | – | – | – |
| Capital Expenditures | – | – | – | – |
| Free Cash Flow | – | – | – | – |